GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MAYNF) » Definitions » Gross Margin %

Mayne Pharma Group (Mayne Pharma Group) Gross Margin % : 56.12% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Mayne Pharma Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Mayne Pharma Group's Gross Profit for the six months ended in Dec. 2023 was $70.3 Mil. Mayne Pharma Group's Revenue for the six months ended in Dec. 2023 was $125.3 Mil. Therefore, Mayne Pharma Group's Gross Margin % for the quarter that ended in Dec. 2023 was 56.12%.

Warning Sign:

Mayne Pharma Group Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.4%.


The historical rank and industry rank for Mayne Pharma Group's Gross Margin % or its related term are showing as below:

MAYNF' s Gross Margin % Range Over the Past 10 Years
Min: 40.14   Med: 50.86   Max: 66.92
Current: 66.92


During the past 13 years, the highest Gross Margin % of Mayne Pharma Group was 66.92%. The lowest was 40.14%. And the median was 50.86%.

MAYNF's Gross Margin % is ranked better than
81.36% of 987 companies
in the Drug Manufacturers industry
Industry Median: 47.04 vs MAYNF: 66.92

Mayne Pharma Group had a gross margin of 56.12% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Mayne Pharma Group was -4.40% per year.


Mayne Pharma Group Gross Margin % Historical Data

The historical data trend for Mayne Pharma Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Gross Margin % Chart

Mayne Pharma Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.52 49.30 48.65 40.14 45.12

Mayne Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.39 35.61 7.32 91.65 56.12

Competitive Comparison of Mayne Pharma Group's Gross Margin %

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Gross Margin % falls into.



Mayne Pharma Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Mayne Pharma Group's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=55.2 / 122.409
=(Revenue - Cost of Goods Sold) / Revenue
=(122.409 - 67.18) / 122.409
=45.12 %

Mayne Pharma Group's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=70.3 / 125.297
=(Revenue - Cost of Goods Sold) / Revenue
=(125.297 - 54.982) / 125.297
=56.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Mayne Pharma Group  (OTCPK:MAYNF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Mayne Pharma Group had a gross margin of 56.12% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Mayne Pharma Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.